Rytmocard 3,5 mg/ml solution for injection Bulgaaria - bulgaaria - Изпълнителна агенция по лекарствата

rytmocard 3,5 mg/ml solution for injection

Софарма АД - Пропафенон - 3,5 mg/ml solution for injection

Propafenon Alkaloid 150 mg film - coated tablets Bulgaaria - bulgaaria - Изпълнителна агенция по лекарствата

propafenon alkaloid 150 mg film - coated tablets

Алкалоид" ЕООД" - Пропафенон - 150 mg film - coated tablets

Propastad 150 mg film - coated tablets Bulgaaria - bulgaaria - Изпълнителна агенция по лекарствата

propastad 150 mg film - coated tablets

stada arzneimittel ag - Пропафенон - 150 mg film - coated tablets

Propastad 300 mg film - coated tablets Bulgaaria - bulgaaria - Изпълнителна агенция по лекарствата

propastad 300 mg film - coated tablets

stada arzneimittel ag - Пропафенон - 300 mg film - coated tablets

Rytmonorm 70 mg/20 ml solution for injection Bulgaaria - bulgaaria - Изпълнителна агенция по лекарствата

rytmonorm 70 mg/20 ml solution for injection

mylan healthcare gmbh - пропафенон хидрохлорид - 70 mg/20 ml solution for injection

Rytmonorm  150 mg film - coated tablets  Bulgaaria - bulgaaria - Изпълнителна агенция по лекарствата

rytmonorm  150 mg film - coated tablets 

mylan healthcare gmbh - пропафенон хидрохлорид - 150 mg film - coated tablets 

Rytmonorm  300 mg film - coated tablets  Bulgaaria - bulgaaria - Изпълнителна агенция по лекарствата

rytmonorm  300 mg film - coated tablets 

mylan healthcare gmbh - пропафенон хидрохлорид - 300 mg film - coated tablets 

Sovrima Euroopa Liit - bulgaaria - EMA (European Medicines Agency)

sovrima

centocor b.v. - идебенон - Фридрих Атаксия - psychoanaleptics, - Лечение friedreich’атаксией.

Onglyza Euroopa Liit - bulgaaria - EMA (European Medicines Agency)

onglyza

astrazeneca ab - Саксаглиптин - Захарен диабет тип 2 - Лекарства, използвани при диабет - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

MERON PLUS Itaalia - bulgaaria - Ministero della Salute

meron plus